MET and renal cell carcinoma: As confirmation of a direct effect of c-MET inhibitors on bone metastases and bone cells, literature data reported clinical and pre-clinical evidences that cabozantinib (a tyrosine kinase inhibitor targeting c-MET and VEGFR-2) has a double antitumoral and anti-bone resorptive effects in patients with advanced RCC [49].